



Danish Biotech: venture capital trends and insights



Table of contents.

- 1 Investment in Global, European and Nordics biotech
- 2 Danish Biotech
- 3 Building Biotech companies in Europe
- 4 Investor landscape


Page / 2 dealroom.co

1

Investment in Global, European and Nordics Biotech


Biotech companies globally have reached a combined value of \$2.0T.

Combined enterprise value of Biotech companies by launch year <u>» view online</u>




European biotech companies are now worth \$364B.

Combined enterprise value of Biotech companies




The top 10 most valuable Biotech companies in the Nordics represent 77% of the total value.



Global VC investment in biotech reached an all-time high in 2021, with \$41B raised, a 3.4x increase since 2016.

Combined enterprise value of Biotech companies by launch year <u>» view online</u>



The US leads by VC investment, but biotech is becoming more globally distributed, with startup investment less concentrated around the US.

Venture capital investment in Biotech by destination





2 Danish Biotech

VC investment in Danish biotech startups has more than doubled in the last year alone, hitting \$434M in 2021.

VC investment in Danish biotech » view online

Largest rounds in 2021






Page / 10 Source: Dealroom.co

Rounds below \$100M dominate the Danish biotech VC landscape, counting for 68% of all investment in 2021.


VC investment in Danish Biotech by round size <u>» view online</u>



Page / 11 Source: Dealroom.co


In 2021, 25% of the VC funding in Danish biotech startups came from domestic investors, 35% came from the Rest of Europe and 32% from the US.

VC investment in Danish Biotech by investor source <u>» view online</u>



Page / 12 Source: Dealroom.co


Compared with other European countries, Denmark has been one of the fastest growing by VC investment in biotech.



4 biotech unicorns and \$1B+ exits have been created in Denmark to date.

Biotech unicorns founded in Denmark


» view online



Year \$1B+ valuation reached


European biotech: 34 unicorns and 82 future unicorns (14% Denmark+Sweden).

European Biotech unicorns and future unicorns



Exits for Danish biotech startups are slowly ticking up, with notable IPO like Zealand Pharma.

Number of exits of Danish biotech startups <u>» view online</u>




Page / 15 Source: Dealroom.co

3


Building Biotech companies in Europe

Graduation rates in Europe of Biotech startups are higher initially, and then fall in line with Healthtech and the broader market.




Page / 17 Source: Dealroom.co

It takes (a bit) more time and capital to build a healthtech and biotech startup in Europe.



Page / 18 Source: Dealroom.co

Exciting things are happening at the intersection of Biopharma & Healthtech. Traditionally two different silos, now increasingly overlapping domains.




Page / 19 Source: Dealroom.co

Biotech startups have a longer cashburn. But advancements in AI, and more experienced talent pools could bring them more in line with regular startups.


Regular startup

Exploit new but proven technologies Validate product-market fit as early as possible R&D and patent ownership is rare




Biotech startup

Long and costly testing phases
Discovery phase becoming shorter *
Less market risk **



180+ AI-based solutions making drug discovery faster and more effective

» view online



Source: Dealroom.co.

^{*} AI, mRNA, digital therapeutics and gene editing make biotech gradually more like tech startups, at least for discovery phase.

Convergence of Bio & Healthtech bodes well for hubs that are strong in both.





Healthtech Clusters (startups, investors, academia)

Page / 21 Source: Dealroom.co

4 Investor landscape

Selected biotech investors in the Nordics active in the region.

FUND	TYPE	STAGE	NUMBER OF BIOTECH INVESTMENTS	SELECTED EUROPEAN BIOTECH INVESTMENTS			
Novo Ventures	Corporate VC fund	Series B+	144	FREELINE	• Galecto	BIOTECH	X Adaptimmune
HealthCap	VC fund	Series A	57	NORDIC NANOVECTOR	ACTELION	Vivet	OxThera
Almi Invest	VC fund	Seed	29	●Galecto	STRIKE Pharma	LIPUM	xı∩telα
Lundbeckfonden Ventures	Corporate VC fund	Series B+	28	nṁd pharma°	SANIFIT	BIOTECH	PSIOXUS* THERAPEUTICS
Sunstone Life Science Ventures	VC fund	Series A	22	symphogen	OxThera	F26	TARGED
Heartcore Capital	VC fund	Seed	17	F26	ZEALAND PHARMA	ORPHA Z YME	santaris pharma a/s
Industrifonden	VC fund	Seed	15	OxThera	MINERVAX	calliditas	asgard THERAPPUNCS

European Healthtech & Biotech investors.





Check out previous reports.

Global Health and Biotech investment update


European Health & Biotech – H1 2021 update

Health and Biotech – A European showcase

Digital healthcare: patient-first?

Explore the Health Ecosystem.

» health.dealroom.co





owered by





Healthtech & biotech venture funding needs fresh data!

Welcome to the first <u>dealroom.co</u> weekly health newsletter! <u>Subscribe here</u> for updates, and tell a friend!

I'm <u>Laura</u>, health specialist at Dealroom's and I'll be writing weekly about key news and events about healthtech and biotech, taking a deep dive each week into Dealroom's rich data on the sector to identify important and sometimes counterintuitive trends.

Global investment in healthtech is on a record pace and could reach €55-60 billion this year



Get the latest weekly insights, with the health newsletter.

» Sign up

dealroom.co